Therefore, in the context of genotoxicity, SGK1 may escape treatments targeting PI3K and AKT1 inhibition in cancer cells, a setting where the small survival advantage conferred by active SGK1 may prove most significant. This evidence concerns the gene AKT1 and cancer.